What is it about?
Colorectal cancer is one of the most common causes of cancer-related deaths worldwide, and considered as a heterogeneous disease. Our meta-analysis demonstrated for the first time that LCC had markedly superior anti-EGFR mAb treatment benefit compared with RCC.
Featured Image
Read the Original
This page is a summary of: Primary Tumor Site and Anti-EGFR Monoclonal Antibody Benefit in Metastatic Colorectal Cancer: A Meta-Analysis, Future Oncology, January 2017, Taylor & Francis,
DOI: 10.2217/fon-2016-0468.
You can read the full text:
Contributors
Be the first to contribute to this page
